What exactly is on-treatment remission in psoriasis? Listen as rheumatologist Dr. Jeffrey Stark discusses this question with dermatologist Dr. April Armstrong and patient advocate Elizabeth Park.

On-treatment remission is a relatively new term being applied to the management of psoriasis. What does this mean for treatment goals and why is it important to address that last 10% of residual skin involvement? is it truly possible to attain skin clearance? Listen as rheumatologist Dr. Jeffrey Stark, head of medical immunology at UCB asks such questions and more with internationally recognized dermatologist and researcher Dr. April Armstrong, Chief of Dermatology at UCLA and patient advocate Elizabeth Park offering her perspective of living with plaque psoriasis since age 11.

The intent of this episode is to identify what on-treatment remission is and why it is important to achieve in the management of psoriasis.

This episode is sponsored by UCB.

Timestamps:

0:00 Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. April Armstrong, Professor and Chief of Dermatology, University of California Los Angeles (UCLA) and patient advocate Elizabeth Park who shares her perspective on living with psoriasis.

1:05 The evolution of psoriasis management over the last 15 years from a better understanding of the disease and treatment to attain clear skin.

3:30 Elizabeth's early days of diagnosis and management of her psoriasis at a young age.

7:20 How talking to my doctor and advocating for myself changed my psoriasis management.

8:47 Why clearing even residual psoriasis plaques is important to reducing the inflammatory storm and subsequent risks associated with psoriasis.

11:43 Psoriasis is more than what's visible on the skin.

12:08 How Elizabeth stays vigilant about changes and chooses to live her life.

13:00 The concept of on-treatment remission vs a cure, and how it relates to psoriasis and guidelines in use for other diseases.

16:14 The official definition of on-treatment remission in psoriasis.

19:35 The mental load of having psoriasis and what clearance or remission means to Elizabeth.

21:56 Nuances of on-treatment remission vs tight disease control.

23:56 As a chronic disease, ongoing treatment is necessary.

26:15 We are living in an exciting time where through use of advanced therapies, clearance is possible for many people.

Key Takeaways:

· Introduced in June 2025 through a consensus statement from the Medical Board of the National Psoriasis Foundation, on-treatment remission is a new view of managing psoriasis made possible through a greater understanding of the disease and the evolution of systemic treatments.

· Attaining complete clearance and remission of psoriasis is possible with current and ongoing treatment.

· Intervening early in psoriasis management to control the cytokine storm and attain remission may help prevent progression of related comorbidities like cardiovascular disease or psoriatic arthritis.

Guest Bios:

April Armstrong, M.D., M.P.H. is an internationally renowned dermatologist and clinical researcher who is a Professor and Chief of Dermatology at the University of California Los Angeles (UCLA) where she specializes in inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa (HS). Dr. Armstrong is also the Co-Director for Network Resources at the UCLA Clinical and Translational Research Institute. She has conducted over 150 clinical trials and published over 600 articles in scientific journals. Dr. Armstrong holds multiple leadership positions including Past Chair of the National Psoriasis Foundation Medical Board, Co-President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), councilor for the International Psoriasis Council, and board member for the International Dermatology Outcome Measures, and the American Academy of Dermatology.

Elizabeth Park is a patient advocate and volunteer for the National Psoriasis Foundation. She developed plaque psoriasis in 2008 after being misdiagnosed with seborrheic dermatitis. For most of her adolescence she managed her scalp psoriasis with topicals and phototherapy. In college her psoriasis became worse and she sought other treatment options which included oral systemic treatments and biologics. She is vigilant about changes to her skin and does what she can to live a healthy life to stay on top of her disease management.

Resources:

"Redefining Remission: A new definition for patients, providers and payers" Advance Online. S. Schlosser. July 2025.

April W. Armstrong, MD, MPH; Geroge C. Gondo, MA; Joseph F. Merola, MD, MMSc; et al "Defining On- Treatment Remission in Plaque Psoriasis" A Consensus Statement from the National Psoriasis Foundation Medical Board. JAMA Dermatology, June 2025.

Description:

Do you wonder if TB testing is needed when on a biologic for psoriasis and/or psoriatic arthritis and why? Hear the answer to such questions and more from dermatologist Dr. G. Scott Drew as he addresses recent recommendations.

Join host Archie Franklin as he discusses the latest recommendations from NPF and the International Psoriasis Council about routine testing for tuberculosis (TB) with treatments for psoriasis and psoriatic arthritis such as TNF-inhibitors, IL-17's, IL-23's and others with NPF Medical Board member and leading dermatologist Dr. G. Scott Drew from Mid-Ohio Dermatology.

This episode identifies when a screening for tuberculosis (TB) is needed based on the type of treatment for psoriasis and psoriatic arthritis given recent recommendations from the National Psoriasis Foundation and the International Psoriasis Council.

Timestamps:

(0:00) Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. G. Scott Drew. (1:00) What is tuberculosis (TB) and why testing is required with TNF-alpha inhibitors. (4:22) Frequency of testing for TB and if false positive results occur. (6:15) Do other immunosuppressants require TB testing? (8:14) Testing may create barriers to access or unnecessary testing. (11:03) Release of new recommendations from the IPC and the NPF Medical Board offering guidance of when to test for tuberculosis prior to and during treatment of psoriatic disease. (15:37) No longer need to wait to start therapy like the IL-17's or IL-23's to see the impact on quality of life. (18:26) TB recommendations for other targeted medications like JAK inhibitors, PDE4, or the new oral IL-23 agent. (19:15) Implications of the recommendations for clinical trials. (20:13) Become a member of NPF and visit the website to access resources and stay aware of the latest information impacting the care and treatment of psoriasis and psoriatic arthritis.

Key Takeaways:

· Due to the contagious nature of tuberculosis, a mycobacteria infection that affects the lungs and other parts of the body, and the increased risk associated with suppressing TNF-alpha, a TB screening is required prior to initiating and during some treatments for psoriasis and psoriatic arthritis.

· With more advanced and targeted psoriatic disease treatments now available, the National Psoriasis Foundation and the International Psoriasis Council joint position statement recommends that TB screening is no longer needed with use of IL-17 or IL-23 treatments.

· TB screening may still be appropriate for specific populations and when symptoms are present based on a clinician's assessment.

Guest Bio:

Dr. G. Scott Drew is a medical and surgical dermatologist with Mid-Ohio Dermatology Associates where he specializes in inflammatory diseases such as psoriasis, believing strongly in dermatology and patient care. He is board certified in both Dermatology and Family Practice. In addition to his clinical practice, Dr. Drew is a member of the clinical faculty at Ohio State University, College of Osteopathic Medicine and participates in multiple dermatologic research protocols at five locations in central Ohio. He has been published in numerous peer-reviewed journals, contributed to scientific symposia, and authored textbook chapters. Dr. Drew is a fellow of the American Osteopathic College of Dermatology and the American Academy of Dermatology, he is past president of the Marion Academy of Medicine, a member of the American Osteopathic Association, and is a member of the National Psoriasis Foundation's Medical Board contributing to the development of guidelines and consensus statements. He is passionate about education providing lectures both nationally and internationally on medical, surgical, and cosmetic dermatology. Resources:

Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. Journal of the American Academy of Dermatology. Vol . 94/3; P802-809. March 2026.

Description:

How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.

Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.

This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.

Thank you to Lilly for their support of this program activity.

Timestamps:

(0:00) Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.

(1:35) What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss.

(3:29) Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis.

(5:23) The metabolic, cardiovascular, and psoriatic disease convergence.

(7:19) Will reduction of inflammation impact cardiovascular risk?

(10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese.

(13:45) Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis.

(17:06) Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1 receptor agonist therapy.

(19:07) Having the conversation of adding a GLP-1 RA medication to a treatment regimen.

(22:40) The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways.

Key Takeaways:

· Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.

· Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.

· The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.

Guest Bios:

Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.

Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board".

Resources:

"The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan

"NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release

"Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger.

Description:

"When joint pain is present, the diagnosis of psoriatic arthritis needs to be made as soon as possible, ideally within six months to limit joint inflammation" Dr. Vinod Chandran mentions as he discusses efforts to identify a diagnostic test for those at risk of developing psoriatic arthritis.

Join host Jeff Brown as he speaks with leading rheumatologist and clinician scientist Dr. Vinod Chandran, Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto to learn more about the progress and promising results towards developing a psoriatic arthritis diagnostic test through multi-omic assays and identifying the distinct differences between psoriasis and psoriatic arthritis.

This episode provides an update on the progress to date of the NPF PsA Diagnostic Test grant initiative which has shown promising results with a potential test entering prospective study in multiple sites soon.

Thank you to Johnson and Johnson for their support of this program activity.

Timestamps:

(0:00) Intro to Psoriasis Uncovered & guest welcome rheumatologist Dr. Vinod Chandran.

(0:52) It is challenging to diagnose psoriatic arthritis with many factors leading to a delay in diagnosis.

(4:56) The start of Dr. Chandran's involvement with the PsA Diagnostic Test Grant project.

(7:55) The different types of omics and the definition of multi-omic.

(9:57) How the multi-omic approach is used to find biomarkers relative to a specific disease pattern.

(11:08) Development of a predictive or prevention-based test using gene expression.

(13:46) First year results identify 200 markers across different omic approaches that distinguish psoriatic arthritis from psoriasis.

(14:58) The significance of MRNA vs mIcroRNA's use in development of a diagnostic test and how critical that is to dissemination of a potential test.

(17:08) Identifying the skin-joint axis in relation to different types of arthritis.

(20:20) Next steps to moving the diagnostic test research forward as a prospective study in multiple sites and the cost effectiveness of delivering the test.

(23:13) If you have psoriasis, musculoskeletal, back, and joint pain think of psoriatic arthritis and be diagnosed early to maintain a good quality of life.

Key Takeaways:

· Given challenges associated with diagnosing psoriatic arthritis and the impact on quality of life, in 2019 NPF launched the PsA Diagnostic Test Grant project with the goal of developing an early stage test that would identify and diagnose those with psoriatic arthritis before debilitating joint damage begins.

· Progress towards a PsA Diagnostic Test includes the study of multi-omic data sets where 200 distinct biomarkers have been identified leading to a greater understanding of the different pathways between psoriatic arthritis, psoriasis, and the skin joint axis.

· A potential diagnostic test is now moving towards the prospective study phase. Until the test is available and if joint pain is present and you have psoriasis, ask your health care provider if it could be psoriatic arthritis and treat appropriately.

Guest Bio:

Vinod Chandran, MBBS, MD, DM, PhD is a rheumatologist, clinician scientist, and Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto where he is also a Professor of Medicine. His specialties include internal medicine, immunology, rheumatology, and genetic epidemiology. His research focus is on the development of biomarker-based strategies to improve early diagnosis and prognosis of psoriasis and psoriatic arthritis, identification of new treatment targets especially for those who do not respond to current therapies, and strategies to reduce the impact of disease. Dr. Chandran is a Co-Vice President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis or GRAPPA. He is an active collaborator in a multi-center research consortia such as the International Psoriasis and Arthritis Research Team and the Spondyloarthritis Research Consortium of Canada. Dr. Chandran is the recipient of research funding from the National Psoriasis Foundation for his work in identifying a "Multi-omic Diagnostic Test for PsA in Psoriasis Patients".

Resources:

"Understanding the NPF Psoriatic Arthritis Diagnostic Test Grant Outcomes" Advance Online. February 18, 2026.

"Managing Chronic Pain with Psoriatic Arthritis" Psoriasis Uncovered podcast episode with physiatrist Dr. Erin Maslowski, LB Herbert who lives with psoriatic disease, and moderator Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease.

Glossary of terms:

mRNA: Messenger RNA carries protein information or instructions from the DNA in a cell's nucleus to the cell's interior where the sequence is read and translated into corresponding amino acids for growing protein chains.

Micro-RNA (miRNA): Micro-RNA act as the regulator. They are short and bind to specific target mRNA's to degrade or inhibit production of protein.

Description:

"What is metabolic disease and why do I have it on top of psoriatic disease?" Hear dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan explore this collision of diseases and how you can take control to help reduce the impact of inflammation.

Join host Corinne Rutkowski as she discusses why metabolic disease occurs with psoriasis and psoriatic arthritis and what can be done to improve overall health with dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and Danielle Cahalan, a registered dietitian and coach with All Access Dietitians. Listen as they also discuss the four pillars of health, the latest evidence around use of the Mediterranean Diet with psoriatic disease, key nutrients that impact overall health from omega 3's, polyphenols, and fiber, to making small sustainable changes.

This episode offers information to help explain the connection between metabolic and psoriatic disease and what can be done to decrease health risks associated with both diseases through sustainable changes.

Timestamps:

(0:00) Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and registered dietitiand and coach Danielle Cahalan.

(1:27) Definition of metabolic disease and why the risk is higher among those with psoriasis or psoriatic arthritis.

(3:11) How this bi-directional relationship impacts the management of psoriasis and psoriatic arthritis.

(6:54) The four pillars of health that can be used to reduce the risk of metabolic disease.

(11:17) Does an anti-inflammatory diet exist?

(13:46) What is the Mediterranean diet and the foods that are typically included.

(16:32) The impact of the Mediterranean diet on systemic inflammation, metabolic health, and severity of psoriatic disease.

(21:03) The three types of healthy fats – what they are, how they work, and where to find them.

(24:50) The high polyphenol Mediterranean diet from what that means to choosing nutrient dense, colorful foods.

(28:04) The koebnerization of the gut microbiome and the impact of the Mediterranean diet and high fiber.

(30:59) The DASH diet in combination with the Mediterranean diet lowers oxidative stress and inflammation.

(33:14) Sustainability of the Mediterranean diet and flexing behavioral health changes long term.

(37:43) Start with small habit changes and then build from there to have an impact on your metabolic health.

Key Takeaways:

· Research shows a bi-directional relationship between psoriasis and excess body weight leading to increasing severity of disease, decrease in treatment effectiveness, and the development of metabolic syndrome, a group of conditions which together raise the risk of coronary heart disease, stroke, and diabetes.

· What you choose to eat can make an impact in managing inflammatory markers, metabolic health to increase insulin sensitivity, decrease high blood pressure, improve lipids and the gut microbiome, as well as support neuro protection and decrease cognitive decline.

· Create small sustainable habits that make positive changes to your immune system and gradually work towards building a foundation that benefits your overall health.

Guest Bios:

Renowned dermatologist Ronald Prussick, M.D. is the Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland where he specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails with the latest technology and products. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health. He first became interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET?CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick also participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the NPF, which offered a review of studies addressing the impact of dietary interventions in people with psoriasis and psoriatic arthritis. Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and provides education oversight to the organization and its Executive leaders.

Danielle Cahalan, MS, RDN is a licensed and registered dietitian and coach with All Access Dietitians which offers virtual nutrition support services in AZ, CA, CO, CT, FL, IL, IN, MA, MO, MT, NJ, NY, NC, OR, PA, SC, TX, VA, WA, WI, and WY. All Access Dietitians infuses the science of motivation, habit formation, and sustainable behavior change into every session that addresses weight management and metabolic health, to women's health and digestive support. Danielle's primary focus during sessions is to help her clients find that intersection between enjoyment and satisfaction with their food choices that also support their health through sustenance. It's about finding that balance between feeling empowered, energized, and confident in the ability to make decisions that impact health, wellness, and longevity.

Resources:

"Mediterranean Diet Pyramid: Guidelines for Healthy Eating" © 2009 Oldways Preservation and Exchange Trust www.oldwayspt.org and UCSF Weill Institute for Neurosciences Memory and Aging Center.

DASH Eating Plan (Dietary Approaches to Stop Hypertension). February 25, 2026. NIH (National Heart, Lung, and Blood Institute)

Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. AMA Dermatology . Dec. 1, 2025

The Mediterranean Diet as a Potential Solution to the Gut Microbiome Dysbiosis in Psoriasis Patients Journal of Psoriasis and Psoriatic Arthritis 2024 Jan 9.

Description:

Coping with psoriasis can be challenging when your routine changes. Hear NPF Youth Ambassadors Aditi, Alyssa, and Pierce offer what they do to overcome such challenges when out of their routine.

Join host Kaleigh Welch as she discusses tips for coping with changes that occur when traveling to visit family or friends, going on vacation, camping, or a change in schedule with three amazing NPF Youth Ambassadors Aditi, Alyssa, and Pierce who live with psoriasis. Hear their story from challenges with their initial diagnosis, struggles with insecurities, whether they choose to inform others, and what they do to manage their disease and stress while living their life with confidence to pursue their chosen activities no matter if their routine changes.

This episode features how 3 NPF Youth Ambassadors overcome challenges when out of their routine and how they respond while managing their psoriasis.

(0:00) Intro to Psoriasis Uncovered & welcome to guests Youth Ambassadors Aditi, Alyssa, and Pierce.

(0:55) Overcoming challenges from diagnosis, finding the right treatment, to making choices impacted by living with psoriasis.

(5:44) Tips for what to do and pack when traveling for activities that disrupt the usual routine.

(10:11) Keeping the skin moisturized can be a challenge but find a routine and product that works.

(12:38) Preparing for potential triggers that could initiate the Koebner phenomenon and psoriasis.

(13:33) Managing the impact of stress when out of the routine or traveling.

(16:20) Alyssa's approach to managing fatigue.

(16:53) The impact of diet and exercise when managing psoriasis.

(18:47) Telling others about psoriasis when staying at a friend's house or hotel.

(23:36) Our number one recommendation for when being out of your routine.

(25:39) Be confident about who you are and trust you'll find the right treatment and routine for your psoriasis.

Key Takeaways:

· Being out of your normal routine whether traveling on vacation or for work, camping, staying at a hotel or with family or friends can present challenges to managing your psoriasis.

· Preparing in advance by anticipating medication or over-the-counter needs, telling others, and asking for help can reduce the impact of challenges due to a change in routine.

· Be confident about who you are, find a treatment that works, and learn to live successfully with your psoriasis.

Guest Bios:

Aditi enjoys Carnatic singing, violin, figure skating, and participating in Model UN where students debate global issues, learn diplomacy, international relations, and public speaking. Aditi was diagnosed with psoriasis at 10 years old and has used topicals to manage her disease along with diet, exercise and stress management. Prior to becoming a Youth Ambassador she had never met anyone with psoriasis. She plans to pursue a career in dermatology.

Alyssa is relatively new to the NPF Youth Ambassador program, joining in 2025 to connect with others who also live with psoriasis. Her diagnosis process was challenging and eventually she was diagnosed with guttate psoriasis after being improperly diagnosed and given treatments that didn't fully clear her psoriasis. This experience changed her life both physically and emotionally. Alyssa is a busy student-athlete serving as a member of her school's varsity cheer team and being a star pitcher for her school's softball team.

Pierce connected with NPF right after being diagnosed with moderate to severe plaque psoriasis in 2024 which covered over half of his body. Together with his mother they learned more about the disease and management with various treatment options from NPF, quickly learning what worked and what didn't. Per Pierce "it was horrible dealing with it for a while because I couldn't hide the plaques." After facing challenges with step therapy and eventually traveling to the Mayo Clinic he found the treatment he needed to help clear his skin. Pierce is very active in golf playing at least 5 days a week. He currently plays for his high school team, the Louisiana Junior Golf Tour, and the American Junior Golf Association (AJGA). Pierce also became a Youth Ambassador to meet others with psoriatic disease.

Resources:

-Meet other teens who have psoriatic disease. Become a Youth Ambassador

-"Traveling Near and Far With Psoriatic Disease" podcast episode.

-"Moisturizing Sensitive Skin" Advance Online. June 11, 2025.

After being diagnosed with psoriasis and psoriatic arthritis, finding a community that understood how life changed meant everything to Jody Quinn, Ben and Kathryn Rifenbark.

Join host Alan Simmons as he addresses life with psoriasis and psoriatic arthritis before and after finding the National Psoriasis Foundation with 3 amazing volunteers – Jody Quinn, Ben and Kathryn Rifenbark. Hear their story from struggles with initial diagnosis, being an advocate for their own health care, to how they chose to become part of a community and help others with the disease to support the mission of the National Psoriasis Foundation. Being part of NPF truly changed their lives!

This episode features how 3 volunteers changed their lives to navigate the challenges of being diagnosed with psoriatic disease to taking steps to help others in need and the mission of the National Psoriasis Foundation.

Timestamps:

· (0:00) Intro to Psoriasis Uncovered & guest welcome Jody Quinn, Ben and Kathryn Rifenbark.

· (0:59) What life was like for Ben and Kathryn from diagnosis to finding a community through NPF.

· (2:42) Facing psoriatic arthritis first and being undiagnosed for years was challenging for Jody.

· (4:48) Finding control over psoriatic disease by becoming an advocate for change.

· (6:15) Diving into the deep end to help fundraising efforts.

· (7:03) Becoming a One to One mentor to help answer questions from others and share the positive impact NPF makes in our lives.

· (8:52) Making connections to help raise awareness about psoriatic disease from resolutions to public service

announcements and lighting bridges in NPF's colors -- orange and blue.

· (10:40) Receiving the NPF Volunteer Innovator award and being a Psoriatic Ambassador Honoree.

· (12:04) Benefits we received from attending the IMPACT Summit Volunteer Leadership Conference.

· (15:11) Jody's single most life-changing event was attending the FDA Drug Development meeting.

· (17:23) It's important to advocate for your own health care needs while continuing to learn from others and resources

available through the NPF.

· (19:14) Every step no matter how small or large makes an impact and is important.

Key Takeaways:

· Being diagnosed with psoriasis and psoriatic arthritis is a life-long journey which can be made easier by finding the right health care, education and resources, as well as a community that understands what it means to live with psoriatic disease. You are not alone.

· You can take control over your disease by advocating for policy changes that affect all patients regardless of what chronic disease they may have. Let your voice be heard.

· Every step you take no matter how small or large makes a difference – whether it's learning more about psoriatic disease, sharing your story, or participating as a volunteer. You can make an impact. Start your journey with NPF today! Become a volunteer.

Guest Bios:

Jody Quinn has a long history of involvement with NPF as a volunteer. She first became a volunteer in 2012 after seeking to connect with others who have psoriatic disease during a Walk event. She remembers meeting an inspirational group of volunteers. Wanting to learn more about her disease she attended More Than Skin Deep and Be Joint Smart events and served as a moderator. Continuing her path of involvement she attended Volunteer Conferences in Chicago and San Francisco. In 2016 she attended her first Capitol Hill Day followed by the FDA Patient Focused Drug Development (PFDD) meeting. Her involvement was so profound she remains an active advocate promoting research and legislation to enhance access to treatments and health care services. Jody has been so successful in promoting awareness about psoriatic disease, she was awarded the NPF Volunteer Innovator Award in 2017. In 2025 she was also named as the New England Soiree Psoriatic Ambassador Honoree for her impactful service and tireless advocacy. In her words, "I volunteer because it gives me some control over what often feels like a completely uncontrollable disease. It allows me to have a say in what is happening with my life and my disease, which I didn't have before. I also volunteer so that others don't have to go through the same long and difficult journey to diagnosis and treatment that I did."

Kathryn & Ben Rifenbark discovered the NPF after many challenges with finding the right diagnosis for Ben's psoriasis. Through a local NPF Take ACTION event Ben quickly learned he wasn't alone in living with his disease, while Mom, Kathryn, gained as much information as she could. After the event, they soon became part of the NPF community with Ben serving as the 2024 Take ACTION Ambassador and a leading peer-to-peer fundraiser. He shared his story and a motivational message at last year's Take ACTION event to help encourage others to support the mission of the NPF. Ben is also an IMPACT Ambassador learning how to advocate for himself and has participated in the IMPACT Summit representing the amazing youth who are part of our NPF Community. Kathryn is now a mentor sharing what she's learned with other parents.

Resources:

Volunteer Spotlight: Jody Quinn May 1, 2025

Ambassador, Advocate and Mentor Advance Online December 11, 2025. (Ben & Kathryn Rifenbark)

Her Nails Held the Secret to Her PsA Advance Online Updated September 29, 2025.

Description:

Learn why advocating for care is crucial when moderate to severe plaque psoriasis develops at a young age or in high-impact sites, and how advanced biologic therapies can offer effective solutions for those that may be undertreated.

Join moderator Kaitlin Walden, patient advocate Carolyn, and dermatologist Dr Candrice Heath as they discuss the realities of living with moderate to severe plaque psoriasis at a young age, as well as adult patients with plaque psoriasis in high-impact sites, like the scalp, nails, and face. Carolyn shares her personal journey with moderate to severe plaque psoriasis and how it has continued from childhood into adulthood, while Dr Heath offers insights to help caregivers and patients navigate treatment approaches, including when and how a biologic therapy may be helpful.

This episode addresses challenges associated with living and treating moderate to severe plaque psoriasis in children and adults.

This episode is sponsored by Johnson & Johnson. Please see Important Safety Information and full Prescribing Information for the product mentioned in this episode.

Timestamps:

· (0:23) Intro to Psoriasis Uncovered and guest introductions from dermatologist Dr. Candrice Heath and Carolyn, a patient advocate living with plaque psoriasis and psoriatic arthritis.

· (1:22) Information about, and pivotal data for, TREMFYA® (guselkumab), a biologic used to treat adults and children 6 years and older who weigh at least 88 lbs or 40 kilograms with moderate to severe plaque psoriasis.

· (3:48) Living with psoriasis as a child can be difficult with challenges in being diagnosed correctly and receiving appropriate treatment.

· (6:17) A dermatologist's view of children and adolescents living with plaque psoriasis including in high-impact sites.

· (8:14) It's important to advocate for yourself and the best possible care.

· (9:37) Open communication with your dermatologist helps identify the best possible treatment plan, which is dependent on several factors including the availability of new treatment options.

· (12:05) Carolyn's biggest challenge is managing her psoriasis and then psoriatic arthritis.

· (14:20) Results of the SPECTREM clinical trial addressing treatment of adults with moderate plaque psoriasis in high-impact sites.

· (17:38) Find the support and information you need to find the right treatment.

· (21:48) Important Safety Information about TREMFYA® (guselkumab).

Key Takeaways:

· Plaque psoriasis can be challenging both physically and emotionally for children and adults – especially when high-impact site involvement (such as the face, scalp, armpits, and groin) is present.

· Individual treatment plans vary and are based on several factors, including the severity of psoriasis, dosing schedule, cost, or route of administration. Finding the right treatment for plaque psoriasis is a collaboration between a dermatologist, the patient, and/or family (should the patient be a child).

· A number of medicines that treat plaque psoriasis from the inside out, including biologics, are now available for children and adults. Such treatment options are continuing to expand.

Guest Bios:

Candrice Heath, M.D. is a highly respected triple board-certified dermatologist who sees both children and adults at Howard University Hospital in Washington DC where she is also an Associate Professor in the Department of Dermatology. She is board-certified in dermatology, pediatrics, and pediatric dermatology.

Dr Heath is a nationally recognized speaker, pediatric and adult dermatology clinical researcher, and has held a variety of leadership roles including Chair for the Pediatric Dermatology Research Alliance (PeDRA), Skin of Color and Pigmentary Disorders Focused Group, Skin of Color Society National Secretary-Treasurer, and American Academy of Dermatology Diversity Committee member. Her clinical, research, and teaching interests are shaped by insights gained from her unique practice filled with both children and adults in addition to her passion for exploring the intersection of dermatology and social science.

Carolyn Pugh is a patient advocate and volunteer with the National Psoriasis Foundation who lives with psoriasis and psoriatic arthritis. Carolyn was diagnosed with psoriasis at age 11 after being misdiagnosed and offered treatments that didn't work. Once she was diagnosed with plaque psoriasis some of the initial treatments were difficult and unsustainable. Over the years she has learned to advocate for her own self-care and feels her personal experiences can help empower other adults and parents.

Resources:

· Learn more about treatment options for children and adolescents at Our Spot for Youth and Parents

· For more information about psoriasis in high-impact sites

Hear leading dermatologist Dr. E. James Song and patient advocate Ana Rinck share their perspectives on the use of biosimilars to manage psoriasis and psoriatic arthritis.

The use of biosimilars is growing with 24 currently on the market and more on the way for the treatment of psoriasis and psoriatic arthritis. What does this mean for you? Find out as we explore the use of biosimilars, the impact of interchangeability, what it's like switching to a biosimilar, and what questions to ask your health care provider with leading dermatologist and NPF Medical Board member Dr. E. James Song, Director of Clinical Research at Frontier Dermatology Partners, and patient advocate Ana Rinck who currently uses a biosimilar to treat her psoriasis and psoriatic arthritis.

The intent of this episode is to offer an update on the use of biosimilars and to hear the experience of those who have used biosimilars to manage psoriatic disease.

Timestamps:

(0:00) Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. E. James Song, Director of Clinical Research and Co-Chief Medical Officer, Frontier Dermatology, and patient advocate Ana Rinck, who presents her experience with using a biosimilar to treat psoriasis and psoriatic arthritis.

(0:58) Definition of what is a biosimilar in comparison to a biologic which is also referred to as the original bio-originator or reference product.

(3:10) What biosimilars are available and how they are used.

(4:35) The term interchangeable and what it means for use of a biosimilar.

(5:46) Ana's diagnosis to treatment options starting with use of topicals to ultimately use of a biosimilar.

(7:57) Treatment discussion and choices when faced with diminishing effectiveness within a class of medications. Should a biosimilar be considered as an option?

(9:50) Questions to consider when there's a change in treatment.

(10:57) FDA announcement to simplify the development process for biosimilars and what that means for the future use of biosimilars.

(13:55) What to consider when thinking of a biosimilar as a treatment option and where to find help when needed.

(14:53) The hope and equity of access that biosimilars represent is here for the appropriate individual.

Key Takeaways:

· A biosimilar is an FDA-approved biologic product that behaves and functions like a brand biologic treatment which is also called the reference product or bio-originator. There are no clinically meaningful differences between biosimilars and their reference product.

· The FDA has approved several biosimilars for the treatment of psoriasis and psoriatic arthritis. Some have been identified as interchangeable which means a biosimilar could be substituted for a reference product without a health care provider's approval pending state legislative rules.

· Don't be afraid to ask questions or access resources to assist with preparing for a medication change should that change be initiated either by yourself, your healthcare provider, or your health insurance company.

Guest Bios:

E. James Song, M.D. is a nationally recognized dermatologist and clinical researcher who is also a Clinical Instructor at the University of Washington. Dr Song is recognized as a key opinion leader in treating psoriasis and atopic dermatitis. He is actively involved in the development of new therapies for dermatologic disease and has firsthand experience with treatments before they come to market. Dr. Song has been published extensively in peer review journals and regularly participates in meetings both as a lecturer and attendee. He is also a Medical Board member of the National Psoriasis Foundation. He believes that the best health outcomes come from shared decision making between the patient and physician. Dr. Song strives to help patients understand not only their condition, but all their treatment options.

Ana Rinck is a patient advocate and volunteer for the National Psoriasis Foundation. She developed psoriasis in 2009 following symptoms she noticed for a few years which proved to be challenging to diagnose. She managed for many years on topicals and intralesional injections. In 2018 she was diagnosed with psoriatic arthritis and started use of a biologic realizing she needed to protect her joints from further damage. She now uses a biosimilar to manage her psoriatic disease. Ana owns her own private consulting business and is an Operations and Project Manager.

Resources:

-Learn more about biosimilars, interchangeability, and state substitution rules.

-Armstrong A, Callis Duffin K, Feldman S, Glick B, Kalb R, Reddy S, Schwartzman S, Yamauchi P, Calabrese C, Cordoro K, Desai S, Gladman D, Han G, Hawkes JE, Hsu S, Kircik L, Koo J, Kreuger GG, Lebwohl M, Leonardi C, Lewitt GM, Liao W, Liu C, Markenson J, Merola JF, Orbai A, Prussick R, Richardson V, Soung J, Van Voorhees AS, Wallace E, Weinberg J, Wine Lee L, Harris J, Koons S, Howard L. Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis. National Psoriasis Foundation Medical Board. 2023.

-If you need help finding a dermatologist near you contact the NPF's Patient Navigation Center for assistance.

Description:

Nail psoriasis is tough to treat. Hear Rebecca, a patient who lives with nail psoriasis, and dermatologist Dr. Paul Yamauchi discuss the diagnosis, care, and treatment for this high-impact site.

Join host Roy Pankey as he addresses the complexities of nail psoriasis from diagnosis to coping and the latest research and treatments with leading dermatologist, Dr. Paul Yamauchi from the Dermatology Institute and Skin Care Center and Clinical Science Institute, and Rebecca, a patient advocate with the National Psoriasis Foundation who lives with nail psoriasis. Listen as they discuss the challenges associated with living with nail psoriasis, and what can be done to help manage the disease from self-care to treatment choices – including the latest research developments.

While nail psoriasis can be challenging to diagnose and treat, there are many actions that can be taken to help minimize the impact of this disease.

Timestamps:

(0:00) Intro to Psoriasis Uncovered & guest welcome Rebecca and dermatologist Dr. Paul Yamauchi. (0:58) Signs or changes to nails that indicate nail psoriasis is present. (2:07) Elements and challenges to diagnosing nail psoriasis. (4:41) What is a nail biopsy and how is it done. (5:25) How nail psoriasis relates to psoriatic arthritis. (6:19) What flares my nail psoriasis. (6:57) There are many treatment choices used to treat nail psoriasis based on convenience, impact of disease, preference, and when to expect improvement. (10:13) A personal perspective on medications used to treat nail psoriasis. (10:42) Research results of the latest medications used to treat nail psoriasis. (13:03) Upcoming oral agents that could be effective in treating nail psoriasis. (15:14) Self care tips, use of nail polish and artificial nails. (19:21) Nail psoriasis is challenging to treat. Be patient with yourself and your dermatologist.

Key Takeaways:

· Nail psoriasis presents many challenges from living and coping with the disease to diagnosis and treatment.

· Medication choices for nail psoriasis are based on convenience, impact of disease, and preference for use of topicals, phototherapy, oral agents, and/or biologics.

· Since nail psoriasis takes time to see improvement, it is important to be patient with yourself and your dermatologist.

Guest Bios:

Dermatologist Dr. Paul Yamauchi is President and Medical Director of the Dermatology Institute and Skin Care Center and Clinical Science Institute in Santa Monia, CA. Dr. Yamauchi is a leading expert in the field of psoriasis and has extensive experience treating different types of psoriasis using the latest treatments from topicals to biologics. He is also a Clinical Professor in the Division of Dermatology with David Geffen School of Medicine at UCLA. Dr. Yamauchi has conducted over 200 clinical research trials as principal investigator and is widely regarded as an outstanding clinical research investigator exploring innovative therapies, serving on advisory panels designing protocols that led to FDA approval of various medications. Dr. Yamauchi is a past member of the Medical Board of the National Psoriasis Foundation and is a fellow of the American Academy of Dermatology, and the American Society of Dermatology Surgery.

Rebecca Cohen, is a patient advocate, who was diagnosed with plaque, scalp, and nail psoriasis at age 6 after being adopted by a dermatology physician's assistant who quickly found the best treatment path for her. Prior to that time she was told she had eczema. "My skin actually was really bad as a child. Horrible. Hands, feet, elbows, everything." Eventually after experiencing joint pain and fatigue, she was also diagnosed with psoriatic arthritis around age 20 at which time she started on her first biologic. "I struggled a lot with nail pitting and thickness as a kid and have recently been going through another episode."

Resources:

-Still have questions? Contact the Patient Navigation Center .

-Nail Psoriasis or Nail Fungus? Advance Online June 2025.

-What Your Nails Can Tell Your Doctor About PsA Advance Online March 2020 .